Journal of Applied Hematology

REVIEW ARTICLE
Year
: 2022  |  Volume : 13  |  Issue : 4  |  Page : 176--182

Management of acquired hemophilia: Consensus recommendations for the United Arab Emirates practitioners


Mahmoud Marashi1, Ahmed Aly Basha2, Amar Lal3, Hani Osman3, Hasan Aal Yaseen1, Hasan Ghazal4, Sharukh Hashmi5, Muhammad Khanani6 
1 Department of Hematology/Oncology, Dubai Hospital, Al Ain, UAE
2 Department of Hematology/Oncology, Saudi German Hospital, Al Ain, UAE
3 Department of Hematology/Oncology, Tawam Hospital, Al Ain, UAE
4 Department of Hematology/Oncology, King's College Hospital, Al Ain, UAE
5 Department of Hematology/Oncology, Sheikh Shakhbout Medical, Al Ain, UAE
6 City Abu Dhabi, Pediatric Hematology/Oncology Department, Tawam Hospital, City Abu Dhabi, Al Ain, UAE

Correspondence Address:
Prof. Mahmoud Marashi
Dubai Hospital, Dubai
UAE

Acquired hemophilia A (AHA) is a rare autoimmune condition characterized by spontaneous antibodies formation against coagulation factor VIII (FVIII). In the United Arab Emirates (UAE), the treatment paradigm of AHA varies, leading to heterogeneous patient outcomes. Because AHA cases often present to clinical practitioners with insufficient experience in the disease, diagnosis is sometimes delayed. This document aims to provide recommendations to clinical practitioners in the UAE to bridge the gap of heterogeneous practice in the clinical management of AHA. Structured literature searches in PubMed and Google Scholar with a three-stage Delphi method were conducted. Evidence suggests that prolonged activated partial thromboplastin time before surgery or coupled with acute or recent onset of bleeding is a hallmark of AHA. Treatment using bypassing agents is recommended in AHA patients with bleeding. Corticosteroids and rituximab with (out) a cytotoxic agent represent the first-line treatment in patients with FVIII: C <1 IU/dL. Second-line therapy involves agents not utilized in the first round of treatment. Thromboprophylaxis is recommended if FVIII: C has returned to normal levels. These recommendations are intended to improve the clinical practice and awareness of this disorder among hematologists and nonhematologists in the UAE and provide practical diagnosis and treatment advice.


How to cite this article:
Marashi M, Basha AA, Lal A, Osman H, Yaseen HA, Ghazal H, Hashmi S, Khanani M. Management of acquired hemophilia: Consensus recommendations for the United Arab Emirates practitioners.J Appl Hematol 2022;13:176-182


How to cite this URL:
Marashi M, Basha AA, Lal A, Osman H, Yaseen HA, Ghazal H, Hashmi S, Khanani M. Management of acquired hemophilia: Consensus recommendations for the United Arab Emirates practitioners. J Appl Hematol [serial online] 2022 [cited 2022 Dec 4 ];13:176-182
Available from: https://www.jahjournal.org/article.asp?issn=1658-5127;year=2022;volume=13;issue=4;spage=176;epage=182;aulast=Marashi;type=0